of collagen but near-normal platelet aggregation at high collagen concentrations. 7, 9 BTK has also been shown to work in concert with tyrosine kinase expressed in hepatocellular carcinoma (TEC) in platelets to mediate collagen-induced platelet aggregation via phospholipase Cγ2 activation. [7] [8] [9] [10] Platelets from BTK/TEC double KO mice were completely unresponsive or severely suppressed upon stimulation with a wide range of collagen concentrations. 9 These findings suggest that TEC may partially compensate for loss of BTK function at least in mice; however, the role of TEC in collagen-induced platelet activation in humans has not been fully established.
Ibrutinib, a first-in-class, once-daily, inhibitor of BTK, is approved for treatment of various B-cell malignancies [11] [12] [13] [14] [15] [16] as well as chronic graft-vs-host disease following failure of ≥1 line of systemic therapy. Ibrutinib provides sustained BTK engagement and is effective after daily dosing. 17 Ibrutinib treatment has been associated with an increased risk of bleeding-related adverse events (AEs), with most of them being grade ≤2 and seldom grade ≥3. 13, 14, 18 Platelets from patients receiving ibrutinib exhibited reduced collagen or collagenrelated peptide-induced aggregation, 10, 18, 19 while other receptor systems, such as thrombin receptor, adrenergic receptor, and P2Y
receptors, were largely unaffected. 20 Because platelets play a central role in hemostasis following vascular injury 21 and maintaining vascular integrity, 22, 23 bleeding-related AEs observed among patients on ibrutinib are generally believed to be associated with platelet inhibition. 7, 10, 19 Indeed, ibrutinib has been shown to inhibit collagen-induced platelet aggregation in healthy donors, donors taking warfarin, and donors with severe renal dysfunction with IC 50 values between 0.8 and 4.6 μmol/L (manuscript in preparation). This concept is further supported by studies showing that addition of untreated platelets reverses ibrutinib-induced inhibition of platelet aggregation in vitro 10, 24 and a report that platelet transfusion successfully treated ibrutinib-related central nervous system bleeding. 25 Bleeding has also been reported for other BTK inhibitors either approved or in clinical development, including acalabrutinib/ Calquence ® , 26, 27 tirabrutinib (ONO/GS-4059), 28 and zanubrutinib. 29 Some of these BTK inhibitors have been studied in in vitro or ex vivo platelet assays and demonstrated variable potency and selectivity. It has been suggested that off-target inhibition of TEC by BTK inhibitors may be responsible for the increased incidence of bleeding seen in patients. 26 In addition, past studies only evaluated the BTK inhib- 
| MATERIAL S AND ME THODS

| BTK inhibitors
All BTK inhibitors were synthesized at Pharmacyclics LLC (Sunnyvale, CA, USA) including ibrutinib, acalabrutinib, tirabrutinib, RN486, and zanubrutinib. Figure S1 . To measure cell proliferation, TMD8 cells were plated into 96-well plates and treated for 72 hours. Proliferation was assessed using the CellTiter-Glo ® assay (Promega, Madison, WI, USA).
| Biochemical kinase assays
| Cellular activity assays
| Human platelet preparation and aggregation assay with light transmission aggregometer (LTA)
Fresh venous blood samples were collected from healthy drug- In general, two groups of donors were identified, and the collagen concentrations used for each group were 100 and 75 μg/mL.
| Statistical analysis
Data are presented as mean ± SD for in vitro studies. CalcuSyn software (Biosoft, Great Shelford, Cambridge, United Kingdom) was used to calculate IC 50 for inhibition of platelet aggregation by inhibitors. GraphPad Prism (GraphPad Software, La Jolla, CA, USA; Version 7) was used for correlation analysis using the Pearson correlation calculation and two-sided P values. IC 50 values for on-and off-target cellular activity of different compounds were calculated using GraphPad Prism. Comparison of differences among multiple compounds was analyzed by non-parametric one-way analysis of variance (ANOVA), followed by a Mann-Whitney test to determine differences between compounds.
| RE SULTS
| The activity of BTK inhibitors on BTK and TEC in biochemical and cellular assays
The potency and selectivity profiles of BTK inhibitors in in vitro assays using recombinant enzymes have been notably inconsistent in TA B L E 1 Comparison of kinase activity of ibrutinib and acalabrutinib on BTK and TEC by multiple assay platforms previous reports, presumably due to utilization of different assay platforms and assay conditions. We therefore examined ibruti- values of BTK and TEC, validating the assay sensitivity ( Table 2 ). As expected, ibrutinib was more potent against BTK than the other covalent BTK inhibitors and had the highest potency among all four inhibitors against TEC. However, there was no significant difference among the three covalent BTK inhibitors regarding the selectivity over TEC (Table 2) . Thus, we were unable to demonstrate that acalabrutinib was significantly more selective toward BTK over TEC compared with ibrutinib using multiple assay platforms.
We next examined BTK inhibitors in cell-based assays. BCRmediated CD69 induction in B cells is known to be BTK dependent, 32 Table 3 shows that all three covalent BTK inhibitors and RN486 exhibited potent activity in BTK on-target assays, with ibrutinib demonstrating the greatest potency. Of note, ibrutinib reduced IL-2 production by Jurkat T cells, while no growth inhibitory activity was seen even when increased to more than 3 μmol/L. Inhibition of IL-2 production by ibrutinib likely resulted from its known activity against ITK (Table 2) , another member of the TEC kinase family expressed in T cell lineages.
| Potency of BTK inhibitors on collageninduced platelet aggregation relative to their pharmacokinetic properties
The potency of BTK inhibitors against collagen-induced platelet aggregation was examined with LTA and blood samples from healthy volunteers. The sensitivity of platelets to collagen stimulation is variable among donors, and the same concentration of collagen does not always generate the same magnitude of platelet responses across donors ( Figure S2 ). Therefore, we predetermined the stimulating collagen concentration that produced a half-maximal aggregation response for each donor. Under these conditions, ibrutinib demonstrated a comparable potency in platelet aggregation across donors, which also fell within ibrutinib's clinically achievable plasma exposure range. Importantly, potency of other BTK inhibitors relative to ibrutinib also remained consistent. We thus decided to use this strategy to evaluate all BTK inhibitors in this study using ibrutinib as the control in every assay. 
| Platelet aggregation affected by BTK inhibitors is associated with inhibition of BTK but not TEC
We next expanded our study to a total of 12 BTK inhibitors to fur- 
| D ISCUSS I ON
Bleeding is one of the most common adverse events associated with BTK inhibitors including ibrutinib, acalabrutinib, and zanubrutinib, and inhibition of platelet aggregation has been suggested as a direct cause of bleeding in patients. 38 The activity of BTK inhibitors on platelet activation has often been discussed as a result of BTK inhibition, based on studies of genetic BTK deficiency in humans (X-linked agammaglobulinemia). 7 There are reports that suggest TEC may also be involved in bleeding associated with BTK inhibitors, but these reports are based primarily on studies in BTK and/or TEC KO mice. Biochemical kinase assays using recombinant proteins generate valuable information on the intrinsic potency of kinase inhibitors towards direct targets in relatively simple reconstituted systems.
However, the results of these assays often differ between assay platforms. It is therefore desirable to examine inhibitors in more than one assay platform for a generalized evaluation that better reflects the activity of inhibitors. We compared the potency and selectivity in different assay platforms between ibrutinib and acalabrutinib. Further, we compared the activities of ibrutinib, acalabrutinib, tirabrutinib, and RN486 using the LabChip ® platform and in several cellular assays. Among the four inhibitors, ibrutinib was the most potent in on-target BTK assays (Tables 1-3) .
Consistent with previous publications, acalabrutinib and tirabrutinib were significantly more selective than ibrutinib on ITK, TXK, and BMX; however, no significant selectivity advantage for BTK over TEC was identified between ibrutinib and acalabrutinib with four different biochemical assay platforms in the present study,
TA B L E 4
Comparison between C max and platelet aggregation potency for ibrutinib, acalabrutinib, and tirabrutinib in subjects with B-cell malignancy which was contrary to a previous report by Byrd et al 26 All three covalent BTK inhibitors tested in this study were very potent in both BTK biochemical and B-cell-based assays, with the IC 50 s in the nmol/L range and ibrutinib being the most potent inhibitor (Tables 1-3 ). Although they were less potent in affecting platelet aggregation partially due to the presence of a high amount of protein in platelet-rich plasma, ibrutinib was still more active than acalabrutinib and tirabrutinib with 5.3-and 9.0-fold differences, respectively. These results might imply that ibrutinib induces a higher incidence or more severe bleeding in patients compared with the other inhibitors. However, ibrutinib has a low plasma exposure relative to acalabrutinib and tirabrutinib; for example, the C max of acalabrutinib after 100 mg twice-daily dosing was 1.78 μmol/L, 4.8-fold higher than ibrutinib's 0.37 μmol/L after 560 mg once-daily dosing (Table 4) , eliminating the apparent IC 50 -based advantage for acalabrutinib while still necessitating twice-daily dosing regimen due to a shorter half-life in the plasma (1.13 hours as opposed to 4-6 hours for ibrutinib). 26 In fact, the C max levels of these three covalent inhibitors were close to their respective IC 50 s for platelet aggregation and well within their variation range (standard derivation) ( Figure 1 and Table 4 ), suggesting they all would have similar impacts on platelet aggregation and possibly bleeding risk. Indeed, treatment with acalabrutinib is associated with bleeding events in approximately 50% of patients with hematological malignancies. 27 These observations may also apply to zanubrutinib, another covalent BTK inhibitor in late-stage clinical trials in B lymphoma, as described in reported to regulate PLCγ2 7, 9, 39, 40 ; however, others 32, 41 found that RN486, a highly selective BTK inhibitor with little TEC activity, 
O RCI D
Taisei Kinoshita http://orcid.org/0000-0003-2688-4206
